RYR2 and Alzheimer disease: Since R-carvedilol can significantly reduce the open duration of RyR2 and does not have the ß-blocking effect, it represents a promising treatment for AD without the adverse effects often associated with racemic carvedilol, such as bradycardia and hypotension.